ResMed Target Price Raised 5.1% to A$49.30/Share by Goldman Sachs>RMD.AU
DJ Australian Equities Roundup -- Market Talk
ResMed's Tariff Exemption Should Support Multiples -- Market Talk
Morgans Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Cut 1.6% to A$48.00/Share by Macquarie
ResMed Inc. Files Quarterly Report, Reinforces Market Position
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
ResMed Inc's Earnings Call Highlights Growth and Innovation
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $240 to $290
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Top Gap Ups and Downs on Thursday: IBM, NOW, TXN and More
ResMed Inc. Stock Advances 10.1%, Outperforms Market
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
Research Alert: CFRA Reiterates Buy Recommendation On Shares Of Resmed Inc.
10-Q: Q3 2025 Earnings Report
ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On Thursday
ResMed Is Maintained at Overweight by JP Morgan
Express News | Resmed Inc : UBS Cuts Target Price to $285 From $290